But there are potentially bigger problems in the world of diabetes management, the House of Reps inquiry hears, like the ‘exorbitant’ cost of insulin pumps.
But there are potentially bigger problems in the world of diabetes management, the House of Reps inquiry hears, like the ‘exorbitant’ cost of insulin pumps.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.